Gynecomastia: Its features, and when and how to treat it

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 6, 2004, Pages 511-517

  Bembo, Shirley A ^a   Carlson, Harold E ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIODARONE; AMPHETAMINE DERIVATIVE; ANDROGEN; AROMATASE INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHORIONIC GONADOTROPIN; CIMETIDINE; CLOMIFENE; CYTOTOXIC AGENT; DANAZOL; DIAZEPAM; DILTIAZEM; ESTROGEN; FLUTAMIDE; ISONIAZID; KETOCONAZOLE; METHOTREXATE; METHYLDOPA; METRONIDAZOLE; NIFEDIPINE; NITROSOUREA; PHENYTOIN; RESERPINE; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

BREAST CANCER; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; GYNECOMASTIA; HISTOPATHOLOGY; HUMAN; PREVALENCE; RADIOTHERAPY; REVIEW; SURGICAL TECHNIQUE;

EID: 3042646697     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.6.511     Document Type: Review

References (24)

1. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979; 48:338-340.
2. Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med 1984; 77:633-638.
3. Andersen JA, Gram JB. Male breast at autopsy. Acta Pathol Microbiol Immunol Scand (Sect A) 1982; 90:191-197.
4. Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol 1972; 57:431-437.
5. Carlson HE. Gynecomastia. In: Morley JE, Korenman SG, editors. Endocrinology and Metabolism in the Elderly. Boston: Blackwell Scientific Publications Inc, 1992:294-307.
6. Moore GF, Wattenberg CA, Rose DK. Breast changes due to diethylstilbestrol. JAMA 1945; 127:60-62.
7. Ando S, DeAmicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002; 193:121-128.
8. Mertaini HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998; 79:202-211.
9. Turkington RW. Serum prolactin levels in patients with gynecomastia. J Clin Endocrinol Metab 1972; 34:62-66.
10. DeRaimondo CV, Roach AC, Meador CK. Gynecomastia from exposure to vaginal estrogen cream. N Engl J Med 1980; 302:1089-1090.
11. Gottswinter JM, Korth-Schutz S, Ziegler R. Gynecomastia caused by estrogen containing hair lotion. J Endocrinol Invest 1984; 7:383-386.
12. Hershkovitz E, Leiberman E. Gynecomastia: a review. The Endocrinologist 2002; 12:321-332.
13. Korenman SG. The endocrinology of the abnormal male breast. Ann NY Acad Sci 1986; 464:400-408.
14. Zayed A, Stock JL, Liepman MK, et al. Feminization as a result of both peripheral conversion of androgens and direct estrogen production from an adrenocortical carcinoma. J Endocrinol Invest 1994; 17:275-278.
15. Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490-495.
16. Gray A, Feldman HA, McKinley JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991; 73:1016-1025.
17. Gooren LJG, Daantje CRE. Psychological stress as a cause of intermittent gynecomastia. Horm Metab Res 1986; 18:424.
18. Loriaux DL, Menard R, Taylor A, Pita JC, Santen R. Spironolactone and endocrine dysfunction. Ann Intern Med 1976; 85:630-636.
19. Zachmann M, Eiholzer U, Muritano M, et al. Treatment of pubertal gynecomastia with testolactone. Acta Endocrinol Supp (Copenh) 1986; 279:218-224.
20. Parker LN, Gray DR, Lai MK, et al. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986; 35:705-708.
21. Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynecomastia: results of a prospective study in 55 patients. Ann R Coll Surg Engl 1990; 72:296-298.
22. Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000; 66:38-40.
23. Picker AP. The safety and tolerability of low-dose irradiation for the management of antiandrogen monotherapy. Lancet Oncol 2003; 4:30-36.
24. Daniels IR, Layer GT. Gynecomastia. Eur J Surg 2001; 167:885-892.